More importantly, myelo- and/or monoblasts in the MS lesions exhibit antigenic profiles and express myeloid- and monocytoid-associated antigens, including CD13, CD14, CD33, CD64, CD68 and c-Kit (CD117), as well as lysozyme (14). This evidence concerns the gene LYZ and myeloid sarcoma.